|
|
Monitoring temozolomide treatment of low-grade
glioma with proton magnetic resonance spectroscopy
Murphy PS, Viviers L, Abson C, Rowland IJ, Brada M, Leach MO, Dzik-Jurasz AS
Cancer Research UK Clinical Magnetic Resonance Research Group,
The Institute of Cancer Research and The Royal Marsden NHS Trust, Sutton, Surrey
SM2 5PT, UK.
Assessment of low-grade glioma treatment response remains as much of a challenge
as the treatment itself.
Proton magnetic resonance spectroscopy ((1)H-MRS) and imaging were incorporated
into a study of patients receiving temozolomide therapy for low-grade glioma in
order to evaluate and monitor tumour metabolite and volume changes during
treatment.
Patients (n=12) received oral temozolomide (200 mg m(-2) day(-1)) over 5 days on
a 28-day cycle for 12 cycles.
Response assessment included baseline and three-monthly magnetic resonance
imaging studies (pretreatment, 3, 6, 9 and 12 months) assessing the tumour
size.
Short (TE (echo time)=20 ms) and long (TE=135 ms) echo time single voxel
spectroscopy was performed in parallel to determine metabolite profiles.
The mean tumour volume change at the end of treatment was -33% (s.d.=20).
The dominant metabolite in long echo time spectra was choline.
At 12 months, a significant reduction in the mean choline signal was observed
compared with the pretreatment (P=0.035) and 3-month scan (P=0.021).
The reduction in the tumour choline/water signal paralleled tumour volume change
and may reflect the therapeutic effect of temozolomide.
PMID: 14970853 [PubMed - indexed for MEDLINE]
Source: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=14970853
|
